Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 605-trauma-to-the-skin-subcutaneous-tissue-and-breast-without-mcc
    Ask Trek AI about this page

    Trauma to the Skin, Subcutaneous Tissue and Breast without MCC: Inpatient Reimbursement Overview

    DRG 605 addresses inpatient stays for trauma to the skin, subcutaneous tissue, and breast without Major Complication or Comorbidity, encompassing procedures such as wound debridement and soft tissue repair. Correct assignment impacts Medicare inpatient reimbursement by aligning payment with expected resource use for lower-severity trauma cases.

    Customize your policy alerts

    Sign up for drg 605 policy alerts

    Get alerted when payer policies referencing 605 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 605 Overview

    DRG 605 covers inpatient admissions for treatment of trauma to the skin, subcutaneous tissue, and breast without Major Complication or Comorbidity. Typical cases include debridement, wound repair, and management of soft tissue injuries that do not carry higher-severity comorbid conditions. This Diagnosis-Related Group is important for Medicare payment because it groups similar resource use and sets the base inpatient reimbursement for these lower-severity trauma encounters. Accurate coding and documentation of the absence of Major Complication or Comorbidity determine assignment to this Diagnosis-Related Group and affect payment levels.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute wound management and hemostasis trials evaluating early interventions for traumatic skin and subcutaneous injuries: randomized or pragmatic trials test rapid hemostatic agents, topical dressings, negative-pressure wound therapy, or procedural techniques applied in the emergency or operating room setting for patients with lacerations, degloving injuries, or blunt/penetrating soft-tissue trauma. These studies enroll primarily adult trauma patients admitted for operative or bedside wound management and measure short-term endpoints such as time to hemostasis, infection rates, need for reoperation, transfusion requirement, and length of stay. Evidence from this research informs hospital resource use, procedural coding and reimbursement under the DRG by potentially reducing complications and LOS, which are key drivers of cost for payers and providers.
    • Comparative effectiveness studies of closure methods and reconstructive approaches for complex soft-tissue and breast trauma: observational cohorts or randomized studies compare primary closure, skin grafts, local flaps, and staged reconstructive strategies in patients with varying wound sizes, contamination levels, and comorbidities (e.g., diabetes, peripheral vascular disease). These trials focus on functional and cosmetic outcomes, wound healing time, readmission rates, and downstream need for secondary procedures over weeks to months. For clinicians and payers, such research helps determine which approaches yield the best balance of clinical outcomes and downstream costs, guiding surgical decision-making and appropriate DRG resource allocation.
    • Post-discharge outcomes and care-pathway studies examining infection prevention, rehabilitation, and utilization after inpatient treatment for skin/subcutaneous trauma: prospective cohort studies and quality-improvement trials evaluate discharge protocols, outpatient wound clinic follow-up timing, home health needs, antibiotic stewardship, and rates of emergency revisits or readmission in the 30–90 day window. These studies typically enroll patients transitioning from inpatient care who have risk factors for poor healing (obesity, smoking, immunosuppression) and assess metrics relevant to readmission, prolonged antibiotic use, and overall episode-of-care costs. Results are directly relevant to payers and hospitals aiming to reduce readmissions and total cost of care associated with this DRG by optimizing post-discharge care pathways and bundling strategies.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.